Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Accumulated Expenses (2016 - 2025)

Heron Therapeutics' Accumulated Expenses history spans 14 years, with the latest figure at $9.3 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 482.65% year-over-year to $9.3 million; the TTM value through Dec 2025 reached $9.3 million, up 482.65%, while the annual FY2025 figure was $9.3 million, 482.65% up from the prior year.
  • Accumulated Expenses reached $9.3 million in Q4 2025 per HRTX's latest filing, up from $8.7 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $16.3 million in Q2 2022 to a low of $412000.0 in Q4 2023.
  • Average Accumulated Expenses over 5 years is $9.4 million, with a median of $9.4 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: crashed 88.23% in 2023, then surged 482.65% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $15.3 million in 2021, then plummeted by 77.08% to $3.5 million in 2022, then plummeted by 88.23% to $412000.0 in 2023, then skyrocketed by 286.17% to $1.6 million in 2024, then soared by 482.65% to $9.3 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Accumulated Expenses are $9.3 million (Q4 2025), $8.7 million (Q3 2025), and $6.5 million (Q2 2025).